SN BioScience Report issue

For profit Phase 1
Founded: Sungam Korea, Republic of (2017)

Organization Overview

First Clinical Trial
2020
NCT04640480
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

SN BioScience

Active Ingredients

Drugs in Phase 1 Trials (1)

sn-38 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1